Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 148 clinical trials
Sulodexide VESSEL for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous

pulmonary embolism
deep vein thrombosis
thrombosis
stroke
venous thromboembolism
  • 0 views
  • 26 Jan, 2021
  • 1 location
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

The study will evaluate the effectiveness of a novel, real-time risk prediction model for identifying pediatric patients at risk for developing in-hospital blood clots (or venous thromboembolism

  • 0 views
  • 26 Jan, 2021
  • 1 location
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study

Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of

heparin
pulmonary embolism
anticoagulants
clot
thrombosis
  • 7 views
  • 26 Jan, 2021
  • 78 locations
A Universal Electronic Health Record-based IMPROVE VTE Risk Assessment Model for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients

This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk …

  • 0 views
  • 03 Mar, 2021
  • 5 locations
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

SARS
blood clot
covid-19
anticoagulation therapy
coronavirus infection
  • 50 views
  • 24 Jan, 2021
  • 1 location
Apixaban for Extended Anticoagulation (APIDULCIS)

The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism

pulmonary embolism
deep vein thrombosis
apixaban
thrombosis
apixaban 2.5 mg
  • 6 views
  • 23 Jan, 2021
  • 1 location
Swedish Multicenter Trial of Outpatient Prevention of Leg Clots

Lower limb immobilization is associated with high risk of complications, i.e. venous thromboembolism (VTE) and failed healing. Pharmacoprophylaxis of VTE is in leg-immobilized patients, however

achilles tendon rupture
ankle fracture
intermittent pneumatic compression
fracture treatment
clot
  • 4 views
  • 26 Jan, 2021
  • 1 location
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and …

edoxaban
aspirin
anticoagulants
anticoagulant therapy
  • 196 views
  • 24 Feb, 2021
  • 40 locations
Pregnancy and Risk of Venous Thromboembolism

The management of venous thromboembolism (VTE) risk in pregnancy still remains a challenge. An individual assessment of the VTE risk is crucial for optimal thromboprophylaxis, but there is no

  • 0 views
  • 28 Jan, 2021
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with

anticoagulant
renal function test
renal failure
anticoagulants
vitamin k antagonists
  • 5 views
  • 26 Jan, 2021
  • 39 locations